One concrete data point for the thread. A quick sanity check on any figure quoted here: is it mean or median, is it intention-to-treat or completers, and what was the comparator. Three questions, and they resolve most disagreements in these threads.
If somebody has the primary source to hand I would rather cite it than paraphrase it.
One thing that is still open after NurseAsh_DET’s answer:
How much of the oral variability is the SNAC absorption window and how much is dose, because the two get conflated constantly?
VendorMark said:A quick sanity check on any figure quoted here: is it mean or median, is it intention-to-treat or completers, and what was the comparator.
Coming at VendorMark’s question from a different direction. The gap between trial results and real-world results is consistent and it is not fraud. Trial participants get titration by protocol, scheduled contact, free drug and dietetic support; removing that infrastructure costs a few percentage points every time it has been measured. When your own curve sits below the published mean, that is the likeliest explanation before anything about you or your material.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsClosing the loop on my own question.
Follow-up: moving the tablet to the moment I wake, before anything else, was the whole fix. The dose never changed.
LindaRN_retired said:The gap between trial results and real-world results is consistent and it is not fraud.
LindaRN_retired has the substance of this right. The condition it depends on is worth stating. Worth adding that the tablet is taken daily, so a missed dose costs far less than a missed weekly injection. That is a genuine advantage nobody lists.
Correct me if the detail matters more than I have assumed.